Besvikelse.
To evaluate the efficacy of lopinavir, ritonavir and abidol for the treatment of new coronavirus pneumonia.
method
The clinical data of 134 patients diagnosed with new type of coronavirus pneumonia admitted to Shanghai Public Health Clinical Center from January 20 to February 6, 2020 were retrospectively analyzed. All 134 patients received recombinant human interferon α2b spray treatment and symptomatic supportive treatment. Among them, 52 patients took the antiviral drug lopinavirlitonavir and 34 patients took the antiviral drug abidol. Take any antiviral medication. The treatment effect was compared between the three groups with a median treatment time of 7 days. The comparison between groups was performed using the Kruskal-Wallis test or the chi-square test.
result
Of the 134 patients, 69 were males (51.5%) and 65 were females, aged 35 to 62 years, with an average age of 48 years. The median time to return to normal temperature in the patients in the Abidol group and the lopinavir and ritonavir group was 6 days, compared with 4 days in the control group. The difference was not statistically significant (χ2 = 2.37, P = 0.31). The median time for viral nucleic acid to negative in respiratory specimens of the three groups was 7 days after treatment. The viral nucleic acid negative was 71.8% (28/39) in the lopinavir ritonavir group and 82.6% in the abidol group ( 19/23), the control group was 77.1% (27/35), the difference was not statistically significant (χ2 = 0.46, P = 0.79). 22 patients (42.3%) in the lopinavir ritonavir group, 12 patients (35.3%) in the abidol group, and 25 patients (52.1%) in the control group still showed progressive imaging on the seventh day after treatment (χ2 = 2.38, P = 0.30). Nine patients (17.3%) in the lopinavir ritonavir group, three patients (8.8%) in the abidol group, and four patients (8.3%) in the control group had adverse reactions. There was no significant difference between the three groups ( χ2 = 2.33, P = 0.33).
in conclusion
It has not been found that lopinavirlitonavir and abidol have the effect of improving symptoms or shortening the negative time of nucleic acid of respiratory specimen virus nucleic acid, and its effectiveness remains to be confirmed by further clinical studies.
https://www.reddit.com/r/COVID19/comments/f8qmuw/study_on_effectiveness_of_lopinavir_and_ritonavir/